Literature DB >> 4121701

Chemotactic factor inactivator in normal human serum.

J L Berenberg, P A Ward.   

Abstract

Normal human serum contains an inactivator of chemotactic factors for neutrophilic leukocytes. The chemotactic factor inactivator (CF-I) remains soluble when serum is fractionated with ammonium sulfate (at 45% saturation), directly and irreversibly inactivates chemotactic factors, and it has a broad spectrum of activity as indicated by its inactivation of the chemotactic fragments of human C3 and C5 (third and fifth components of complement), C567, and the bacterial chemotactic factor derived from Escherichia coli. CF-I appears as a biphasic activity according to preparative techniques of sucrose density ultracentrifugation, electrophoresis, and gel filtration. Studies on the interaction of CF-I with the radiotagged C5 chemotactic fragment fail to reveal evidence for irreversible binding as the basis for inactivation. CF-I varies from the anaphylatoxin inactivator in several physical-chemical respects, but evidence does not permit a conclusive statement about the relationship of the two inactivators. CF-I may function as a regulator of inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4121701      PMCID: PMC302376          DOI: 10.1172/jci107287

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

Review 1.  Neutrophil proteases in inflammation.

Authors:  A Janoff
Journal:  Annu Rev Med       Date:  1972       Impact factor: 13.739

2.  Further studies on the chemotactic factor of complement and its formation in vivo.

Authors:  P A Ward; C G Cochrane; H J Muller-Eberhard
Journal:  Immunology       Date:  1966-08       Impact factor: 7.397

3.  Bacterial factors chemotactic for polymorphonuclear leukocytes.

Authors:  P A Ward; I H Lepow; L J Newman
Journal:  Am J Pathol       Date:  1968-04       Impact factor: 4.307

4.  Neutrophil chemotactic factors and related clinical disorders.

Authors:  P A Ward
Journal:  Arthritis Rheum       Date:  1970 Mar-Apr

Review 5.  Hypotensive peptides: bradykinin, kallidin, and eledoisin.

Authors:  E G Erdös
Journal:  Adv Pharmacol       Date:  1966

6.  A neutrophil chemotactic factor from human C'5.

Authors:  P A Ward; L J Newman
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

7.  C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils.

Authors:  P A Ward; J H Hill
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

8.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  38 in total

1.  Comparison of leukocyte count and function in smoking and nonsmoking young men.

Authors:  R C Noble; B B Penny
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

2.  In vitro and in vivo production of chemotactic inhibitors by tumor cells.

Authors:  M C Cohen; J P Brozna; P A Ward
Journal:  Am J Pathol       Date:  1979-03       Impact factor: 4.307

3.  Immunopathology of the lung: a review.

Authors:  K J Johnson; W E Chapman; P A Ward
Journal:  Am J Pathol       Date:  1979-06       Impact factor: 4.307

4.  Characterization of the protease activity in the chemotactic factor inactivator.

Authors:  P A Ward; J Ozols
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

5.  Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action.

Authors:  B McLeod; P Baker; H Gewurz
Journal:  Immunology       Date:  1975-01       Impact factor: 7.397

6.  The effect of D-penicillamine on polymorphonuclear leukocyte function.

Authors:  H Chwalinska-Sadowska; J Baum
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

7.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

8.  Potentiation of schistosome granuloma formation. By lentinan--a T-cell adjuvant.

Authors:  J E Byram; A Sher; J DiPietro; F von Lichtenberg
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

9.  Neutrophil locomotion and serum chemotactic and chemokinetic activities in pustulosis palmoplantaris compared with psoriasis.

Authors:  A Lundin; L Håkansson; G Michaëlsson; P Venge
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

10.  Reduction of carrageenan- bradykinin- and histamine-induced acute inflammation by experimental eosinophilia in rats.

Authors:  H Popper; O Picher; H Auer
Journal:  Immunology       Date:  1982-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.